Complement Factor D Activity Assay

Creative Biolabs offers customized complement Factor D activity assay services to help researchers characterize the functional activity of complement Factor D, also known as adipsin, in alternative pathway activation, disease modeling, inhibitor evaluation, and complement-targeted drug development. Submit your request now to discuss your project with our complement specialists.

Submit Your Request Now

Download our service brochure

Inquiry

Overview of Complement Factor D Activity

Among the three major complement activation routes, the alternative pathway has a unique role as an amplification loop. Even when complement activation begins through the classical or lectin pathway, the alternative pathway can magnify C3 activation and intensify downstream effector functions. Complement Factor D is essential for this amplification process. Unlike many proteases that act on multiple substrates, Factor D displays exceptional substrate specificity. Its principal natural substrate in the complement cascade is Factor B, but Factor B must first bind C3b or C3(H₂O) to become an appropriate substrate. Factor D then cleaves Factor B into Ba and Bb. The Bb fragment remains associated with C3b to form C3bBb, the active alternative pathway C3 convertase. This convertase cleaves additional C3 molecules, generating more C3b and expanding the amplification loop.

Because Factor D acts at this pivotal point, even subtle changes in Factor D activity can influence the magnitude, duration, and localization of complement activation. Reduced activity may impair alternative pathway function and compromise host defense. Excessive or poorly regulated activity may contribute to inflammatory tissue damage. In therapeutic development, Factor D has become a strategic target for controlling complement-driven diseases while potentially preserving upstream recognition mechanisms. A carefully designed Factor D activity assay can therefore answer questions that simple protein quantification cannot address.

Creative Biolabs designs Factor D activity assays to bridge these gaps. Our services are built to provide functional, mechanism-relevant, and decision-ready data for complement research and drug development.

Great Minds Choose Creative Biolabs

Partner with Us

Our Complement Factor D Activity Assay Service

Creative Biolabs provides end-to-end complement Factor D activity assay services covering assay design, reagent preparation, sample handling, optimization, execution, data analysis, and final reporting. Our scientists work closely with each client to define the biological question, select the most suitable assay format, establish controls, and generate quantitative readouts that align with project objectives.

Purified-Protein Factor D Activity Assay

The purified-protein format is suitable for mechanistic evaluation of Factor D catalytic activity, substrate cleavage, and inhibitor potency under controlled biochemical conditions. This format is particularly useful for early-stage inhibitor screening because it minimizes the complexity of whole serum.

Serum-Based Alternative Pathway Factor D Activity Assay

Serum-based assays provide a more physiologically relevant setting for evaluating Factor D function within the complete complement environment. Creative Biolabs can perform serum assays using normal human serum, animal serum, Factor D-depleted serum, Factor B-depleted serum, C3-depleted serum, heat-inactivated controls, or client-provided biological matrices.

Factor D Inhibitor Screening Assay

Creative Biolabs offers customizable screening assays to evaluate inhibitory activity, potency ranking, selectivity, and functional pathway suppression. Test articles may include small molecules, monoclonal antibodies, antigen-binding fragments, peptides, macrocycles, aptamers, fusion proteins, soluble receptors, or other engineered modalities.

Reconstituted Alternative Pathway Assay

A reconstituted assay provides a controlled yet pathway-relevant environment by combining selected purified complement components. This format is useful when researchers need to dissect the contribution of individual proteins, evaluate species-specific compatibility, test engineered variants, or build a defined system for mechanistic drug characterization.

Cell-Based Factor D-Dependent Complement Activation Assay

A cell-based assay can help determine how Factor D activity translates into complement deposition and downstream cellular effects. Creative Biolabs can customize cell selection, serum source, pathway controls, activation conditions, detection markers, and endpoint analysis.

Hemolysis-Based Factor D Functional Assay

Creative Biolabs can configure hemolysis assays for inhibitor potency testing, serum activity measurement, pathway validation, and complement protection studies. Readouts may include absorbance-based hemoglobin release, percentage lysis, dose-response curves, and inhibition profiles.

Discuss Your Needs

Sample Types We Support

Creative Biolabs can work with a variety of sample types, including:

Purified recombinant Factor D, native Factor D preparations

Serum, plasma samples when appropriate for the intended assay

Cell culture supernatants, biological fluids

Drug candidates and inhibitor libraries

Workflow of Complement Factor D Activity Assay

Creative Biolabs proposes conducting the complement FD functional assay utilizing ELISA and hemolysis test.

Complement FD assay. (Creative Biolabs Original) Fig. 1 Workflow of complement factor D functional test.

Design Your Workflow

Technical Considerations for Complement Factor D Activity Assays

Factor D activity assays are powerful but require careful design. The following considerations are important.

Substrate Context

Factor D does not efficiently cleave free Factor B in the same way it cleaves Factor B associated with C3b or C3(H2O). Therefore, assay systems must provide an appropriate substrate context to generate meaningful activity.

Pathway Specificity

Alternative pathway assays should be configured to limit classical and lectin pathway contribution when the goal is Factor D-specific functional evaluation. This may involve buffer selection, activator choice, antibody controls, depleted serum, or inhibitor comparison.

Sample Handling

Complement activity can be altered by improper collection, storage, temperature exposure, repeated freeze-thaw cycles, or inappropriate anticoagulants. Creative Biolabs provides guidance to preserve functional activity whenever client-provided samples are used.

Detection Interference

Some test articles may interfere with colorimetric, fluorometric, or antibody-based detection systems. Creative Biolabs can incorporate interference controls or alternative readouts when necessary.

Key Readouts of Complement Factor B Activity Assay

Creative Biolabs provides a broad range of readouts for complement Factor D activity assay projects. The final readout selection depends on whether the project is focused on direct enzymatic activity, alternative pathway formation, downstream complement activation, or therapeutic inhibition.

Readout	Description
Factor B Cleavage	Direct measurement of Factor B cleavage is one of the most mechanism-relevant readouts for Factor D activity. The assay can quantify intact Factor B depletion or generation of cleavage fragments, including Ba and Bb. This readout is useful for confirming catalytic function, comparing Factor D preparations, evaluating inhibitor effects, and establishing direct biochemical activity.
Bb Generation	Bb is a key marker of alternative pathway activation and C3 convertase formation. Quantifying Bb can provide a sensitive indication of Factor D-mediated Factor B cleavage. Bb detection may be performed using ELISA, immunoblotting, multiplex formats, or other immunoassay technologies depending on project requirements.
Ba Generation	Ba release provides another readout of Factor B cleavage. Measuring Ba can be useful in purified systems, serum assays, and inhibitor studies. Ba quantification may help distinguish upstream Factor B cleavage from downstream amplification effects.
C3b Deposition	C3b deposition reflects alternative pathway amplification on surfaces. In cell-based or surface-based formats, C3b detection can reveal whether Factor D activity results in biologically meaningful complement opsonization. This readout is especially useful for target-cell studies, biomaterial testing, antibody-mediated complement engagement, and disease-surface models.
iC3b and C3 Fragment Profiling	Downstream processing of C3b can generate iC3b and additional fragments involved in immune recognition. Measuring these fragments can help connect Factor D-dependent activation with complement regulation and opsonophagocytic potential.
C3a and C5a Generation	Anaphylatoxin generation provides insight into inflammatory complement signaling. While Factor D acts upstream in the alternative pathway, its activity can influence production of C3a and C5a through amplification. These readouts can be incorporated when inflammatory signaling potential is relevant to the project.
C5b-9 Formation	Terminal complement complex formation indicates progression toward membrane attack complex assembly. In serum or cell-based assays, C5b-9 detection can help determine whether Factor D-dependent amplification proceeds to terminal pathway activation.
Hemolysis or Cell Lysis	Functional cell lysis provides an integrated endpoint reflecting the combined effect of upstream activation, amplification, convertase activity, terminal pathway progression, and membrane attack complex formation. Hemolysis or cytotoxicity readouts are useful for inhibitor evaluation and biologically meaningful pathway suppression studies.

Design Your Customization

Case Studies

Case 1

Complement factor D is linked to platelet activation in human and rodent sepsis

The complement factor D exerts a regulatory role during infection. However, its physiological function in coagulopathy and its impact on the course of an infection remains unclear. Wild-type and CFD-deficient mice were subjected to cecal ligation and puncture to induce sepsis. At several time points, markers of coagulation and the host-immune response were determined. Furthermore, in patients with sepsis or SIRS, CFD levels were related to clinical characteristics, use of antiplatelet drugs and outcome.

FD levels were quantified. (OA Literature) Fig. 2 Height of complement factor D level predicts disease severity.^1,2

References

References

Sommerfeld, Oliver, et al. "Complement factor D is linked to platelet activation in human and rodent sepsis." Intensive Care Medicine Experimental 9.1 (2021): 41. https://doi.org/10.1186/s40635-021-00405-8
Distributed under Open Access license CC BY 4.0, without modification.

What Our Clients Say

"As a complement inhibitor team, we needed more than a simple binding assay. Creative Biolabs helped us generate Factor D activity data that clearly showed whether our candidates reduced Factor B cleavage and downstream alternative pathway activation."

— Director of Discovery Biology, Complement Therapeutics Startup

"We appreciated how Creative Biolabs designed the assay around the biology of Factor D rather than forcing our samples into a standard protocol. The final data package helped us distinguish direct Factor D inhibition from broader complement suppression."

— Principal Investigator, Academic Medical Center

"This was our second complement assay project with Creative Biolabs. The study design was consistent with our previous work, the reference controls were well selected, and the data were directly comparable across lots. Creative Biolabs delivered robust Factor D activity results on time and communicated clearly throughout the project. We especially valued their recommendations for follow-up confirmatory assays."

— Operations Manager, Biotherapeutics Division

"We were working with limited serum samples, and the team helped us design a practical assay layout that preserved material while still generating meaningful alternative pathway activity data. The report was detailed but easy to use. It included the assay conditions, controls, raw data, processed results, IC50 analysis, and interpretation."

— Associate Director, Complement Pharmacology

Frequently Asked Questions

Can the assay distinguish direct Factor D inhibition from downstream complement inhibition?

Yes, assay design can help distinguish these mechanisms. A direct purified-protein assay can evaluate whether a test article blocks Factor D-mediated Factor B cleavage. Serum-based and downstream assays can show whether alternative pathway activation is suppressed. Depleted serum, reconstitution controls, and paired upstream/downstream readouts can further clarify whether inhibition occurs at Factor D or another complement step.

What sample types can be tested?

Supported sample types may include purified Factor D, recombinant proteins, human serum, animal serum, depleted serum, reconstituted matrices, biological fluids, cell culture supernatants, test inhibitors, antibodies, small molecules, peptides, engineered proteins, target cells, erythrocytes, nanoparticles, biomaterials, and other customized materials. Feasibility depends on assay format and available detection reagents.

Can you perform species-specific Factor D activity assays?

Yes, species-specific assays may be available for human, mouse, rat, cynomolgus monkey, and other species depending on reagent availability and cross-reactivity. Species selection is especially important for preclinical studies because inhibitors and antibodies may behave differently across species.

How do you confirm alternative pathway specificity?

Alternative pathway specificity can be supported by using pathway-favoring buffers, appropriate activators, Factor D-depleted serum, reconstitution controls, known pathway inhibitors, heat-inactivated serum, and comparison with classical or lectin pathway controls when needed. The exact control strategy is customized to the assay format.

Can you develop a custom assay if my project does not fit a standard format?

Yes. Creative Biolabs specializes in customized complement assay development. If your project involves a non-standard sample type, unusual species, engineered cell model, novel therapeutic modality, or specialized readout, our team can design a fit-for-purpose workflow.

How should serum samples be collected and stored?

Complement-active serum should generally be collected, processed, aliquoted, frozen, and shipped under conditions that preserve complement function. Repeated freeze-thaw cycles should be avoided. Because optimal handling may vary by study, Creative Biolabs recommends discussing sample preparation before collection or shipment.